| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/14740338.2015.1045874 |
| P698 | PubMed publication ID | 26022669 |
| P2093 | author name string | Sten Nilsson | |
| P2860 | cites work | Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline | Q26852544 |
| Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy | Q27022715 | ||
| Prostate cancer: ESMO Consensus Conference Guidelines 2012 | Q27022847 | ||
| Alpha emitter radium-223 and survival in metastatic prostate cancer | Q29617472 | ||
| Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome | Q30457046 | ||
| Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, [...] | Q33418967 | ||
| Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer. | Q33789188 | ||
| First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases | Q34426777 | ||
| High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities? | Q34576371 | ||
| Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study. | Q34633758 | ||
| 18F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with 223Ra-chloride (Alpharadin) | Q35335407 | ||
| A bone marrow toxicity model for ²²³Ra alpha-emitter radiopharmaceutical therapy. | Q36235572 | ||
| Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer | Q36840731 | ||
| Characterising the castration-resistant prostate cancer population: a systematic review | Q37945316 | ||
| A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. | Q37985149 | ||
| Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial | Q38212374 | ||
| Alpha-emitter radium-223 in the management of solid tumors: current status and future directions | Q38214287 | ||
| Castration-resistant prostate cancer: latest evidence and therapeutic implications | Q38233358 | ||
| Antiangiogenic agents, chemotherapy, and the treatment of metastatic transitional cell carcinoma | Q44080958 | ||
| A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer | Q44872720 | ||
| Phase II study of treatment of advanced ovarian cancer with folate-receptor-targeted therapeutic (vintafolide) and companion SPECT-based imaging agent (99mTc-etarfolatide). | Q53073221 | ||
| Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. | Q53716562 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | radium | Q1128 |
| prostate cancer | Q181257 | ||
| P304 | page(s) | 1127-1136 | |
| P577 | publication date | 2015-05-28 | |
| P1433 | published in | Expert Opinion on Drug Safety | Q5421206 |
| P1476 | title | Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety | |
| P478 | volume | 14 |
| Q33438310 | A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary |
| Q55158890 | A Systematic Review of Clinical Practice Guidelines for Castration-Resistant Prostate Cancer. |
| Q53817267 | Nuclear medicine and the revolution in the modern management of castration-resistant prostate cancer patients: from (223)Ra-dichloride to new horizons for therapeutic response assessment. |
| Q39970827 | Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study |
| Q48144362 | Ra-224 Labeling of Calcium Carbonate Microparticles for Internal α-Therapy: Preparation, Stability and Biodistribution in Mice. |
| Q28079918 | Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer |
Search more.